# A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 inflammation

Published: 24-03-2020
Last updated: 30-01-2025

- The purpose of this study is to evaluate the efficacy of the study drug to lung function, exacerbations and quality of life with patients with COPD. The safety and tolerability of the study drug is monitored as part of this study.

| | |
|---|---|
| **Ethical review** | Approved WMO |
| **Status** | Completed |
| **Health condition type** | Bronchial disorders (excl neoplasms) |
| **Study type** | Interventional |

## Summary

### ID

NL-OMON54320

**Source**
ToetsingOnline

**Brief title**
EFC15805 Notus

### Condition

- Bronchial disorders (excl neoplasms)

**Synonym**
chronic bronchitis

**Research involving**
Human

## Sponsors and support

**Primary sponsor:** Genzyme Europe BV
**Source(s) of monetary or material Support:** Sanofi

## Intervention

**Keyword:** - Chronic Bronchitis, - Chronic Obstructive Pulmonary Disease, - COPD, - Dupilumab

## Outcome measures

### Primary outcome

- Annual rate of acute COPD exacerbation (AECOPD)

### Secondary outcome

- Change in SGRQ

- Improvement in SGRQ

- Change in pre-bronchodilator FEV1 from baseline to Week 52

- Change in pre-bronchodilator FEV1 from baseline to time points up to Week 44

- Change in post-bronchodilator FEV1 lung function

- Change in forced expiratory flow (FEF) 25-75%

- Annualized rate of severe AECOPD

- Time to first AECOPD

- Adverse events

- Potentially clinically significant abnormality (PCSA) in laboratory tests

- Anti-drug antibodies

# Study description

### Background summary

Dupilumab is a drug which has been approved for the treatment of atopic dermatitis, chronic rhinosinusitis
with nasal polyposis and for moderate-to-severe asthma in the US and Europe.

Dupilumab is a biological drug, a monoclonal antibody that blocks the action of proteins called IL-4 and IL-13. Both play an important role in causing the reactions and symptoms of type 2 inflammation, such as in atopic dermatitis, chronic rhinosinusitis with nasal polyposis and for moderate-to-severe astma.

### Study objective

- The purpose of this study is to evaluate the efficacy of the study drug to lung function, exacerbations and quality of life with patients with COPD. The safety and tolerability of the study drug is monitored as part of this study.

### Study design

- Phase 3, double blind, randomized, parallel

### Intervention

- Dupilumab 300 mg/2 ml, administered as 1 SC injection q2w
- Placebo 2 ml, administered as 1 SC injection q2w

### Study burden and risks

- Burden and risks are related to the blood sampling, chest X-ray, injections with study medication and possible side effects of the study medication

# Contacts

**Public**
Genzyme Europe BV

Paasheuvelweg 25
Amsterdam 1105 BP
NL
**Scientific**
Genzyme Europe BV

Paasheuvelweg 25
Amsterdam 1105 BP
NL

# Trial sites

## Listed location countries

Netherlands

# Eligibility criteria

**Age**
Adults (18-64 years)
Elderly (65 years and older)

## Inclusion criteria

Participants with a physician diagnosis of COPD who meet the following criteria at screening:
- Current or former smokers with a smoking history of >=10 pack-years
- Moderate to severe COPD (post-bronchodilator FEV1/FVC ratio <0.70 and post-bronchodilator FEV1 % predicted >30% and <=70%)
- Medical Research Council (MRC) Dyspnea Scale grade >=2
- Patient-reported history of signs and symptoms of chronic bronchitis (chronic productive cough) for 3 months in the year up to screening in the absence of other known causes of chronic cough
- Documented history of high exacerbation risk defined as exacerbation history of >=2 moderate* or >=1 severe** within the year prior to inclusion. At least one exacerbation should have occurred while the patient was taking ICS/LAMA/LABA (or LAMA/LABA if ICS is contradicted). Moderate exacerbations are recorded by the Investigator and defined as AECOPD that require either systemic corticosteroids (intramuscular (IM), intravenous, or oral) and/or antibiotics. One of the two required moderate exacerbations has to require the use of systemic corticosteroids. Severe exacerbations are recorded by the Investigator and defined as AECOPD requiring hospitalization or observation >24 hours in emergency department/urgent care facility
- Background triple therapy (ICS + LABA + LAMA) for 3 months prior to randomization with a stable dose of medication for >=1 month prior to Visit 1; Double therapy LABA + LAMA allowed if ICS is contraindicated
- Evidence of Type 2 inflammation: Patients with blood eosinophils >=300

cells/microliter at Visit 1

### Exclusion criteria

- COPD diagnosis for less than 12 months prior to randomization
- Participants with current diagnosis of asthma according to the Global Initiative for
Asthma (GINA) guidelines, or documented history of asthma
- Significant pulmonary disease other than COPD (eg, lung fibrosis, sarcoidosis, interstitial
lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome, etc) or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts
- Cor pulmonale, evidence of right cardiac failure
- Long-term treatment with oxygen >4.0 L/min OR if a participant requires more than
2.0 L/min in order to maintain oxygen saturation >88%
- Hypercapnia requiring BiPAP
- AECOPD as defined in inclusion criteria within 4 weeks prior to or during the screening period
- Respiratory tract infection within 4 weeks prior to screening, or during the screening period
- History of, or planned pneumonectomy or lung volume reduction surgery.
Patients who are participating in the acute phase of a pulmonary rehabilitation program, ie, who started rehabilitation <4 weeks prior to screening (Note: patients in the maintenance phase of a rehabilitation program can be included)
- Diagnosis of α-1 anti-trypsin deficiency

## Study design

### Design

| | |
|---|---|
| Study phase: | 3 |
| Study type: | Interventional |
| Intervention model: | Parallel |
| Allocation: | Randomized controlled trial |
| Masking: | Double blinded (masking used) |
| Control: | Placebo |
| Primary purpose: | Treatment |

## Recruitment

NL

| | |
|---|---|
| Recruitment status: | Completed |
| Start date (anticipated): | 17-09-2020 |
| Enrollment: | 28 |
| Type: | Actual |

## Medical products/devices used

| | |
|---|---|
| Product type: | Medicine |
| Brand name: | dupixent |
| Generic name: | dupilumab |
| Registration: | Yes - NL outside intended use |

# Ethics review

| | |
|---|---|
| Approved WMO Date: | 24-03-2020 |
| Application type: | First submission |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 25-06-2020 |
| Application type: | First submission |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 12-08-2020 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 28-09-2020 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 30-09-2020 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |

| | |
|---|---|
| Approved WMO Date: | 23-11-2020 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 26-11-2020 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 22-12-2020 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 24-02-2021 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 04-03-2021 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 13-07-2021 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 20-07-2021 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 29-07-2021 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 09-08-2021 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO | |

| | |
|---|---|
| Date: | 05-01-2022 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 10-01-2022 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 21-06-2022 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 21-07-2022 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 03-08-2022 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 27-01-2023 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO Date: | 01-02-2023 |
| Application type: | Amendment |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |

# Study registrations

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

| Register | ID |
|---|---|
| Other | 2018-001954-91 |
| EudraCT | EUCTR2018-001954-91-NL |
| CCMO | NL72959.091.20 |

# Study results

Date completed: 27-05-2024

Results posted: 09-12-2024

**Summary results**
Trial ended prematurely

**First publication**
14-12-2023